title: Antidepressants, metoprolol and the risk of bradycardia.
abstract: Case reports and pharmacologic theory suggest that some antidepressants can interfere with the hepatic metabolism of metoprolol by cytochrome P450 2D6 (CYP2D6), potentially increasing the risk of bradycardia. The objective of this study was to characterize the clinical consequences of this potential drug interaction at the population level. We conducted a population-based, nested case-control study of Ontario residents 66 years of age or older receiving metoprolol. Cases hospitalized for bradycardia were compared with matched controls (4:1) to explore the odds ratio for initiation of antidepressants that inhibit CYP2D6 (fluoxetine and paroxetine) and those that do not inhibit CYP2D6 (fluvoxamine, citalopram, venlafaxine, and sertraline) 30 days before hospitalization. From April 1997 to March 2009, we identified 332,254 older patients continuously receiving metoprolol, of whom 8232 (2.5%) were treated in hospital for bradycardia. The adjusted odds ratio for exposure to fluoxetine or paroxetine compared with other antidepressants 30 days prior to hospitalization for bradycardia was 0.76 (95% confidence interval 0.42-1.37). Among older patients receiving metoprolol, the initiation of antidepressants that inhibit CYP2D6 was not associated with a significant increase in the risk of bradycardia compared with antidepressants that do not inhibit CYP2D6.
authors: Paul A
authors: PA
authors: Kurdyak
authors: Michael
authors: M
authors: Manno
authors: Tara
authors: T
authors: Gomes
authors: Muhammad M
authors: MM
authors: Mamdani
authors: David N
authors: DN
authors: Juurlink
keywords: antidepressants; bradycardia; metoprolol
references: Clin Pharmacol Ther. 2000 May;67(5):567-76
references: 10824636
references: Psychiatr Serv. 2007 Jan;58(1):79-84
references: 17215416
references: Arch Intern Med. 2010 Apr 12;170(7):617-21
references: 20386005
references: Eur J Clin Pharmacol. 2005 Apr;61(2):119-25
references: 15692832
references: J Clin Pharmacol. 2000 Jan;40(1):58-66
references: 10631623
references: JAMA. 2002 Aug 14;288(6):701-9
references: 12169073
references: J Clin Psychiatry. 1998;59 Suppl 15:19-27
references: 9786307
references: J Clin Psychopharmacol. 2005 Jun;25(3):226-9
references: 15876900
references: Mayo Clin Proc. 2008 May;83(5):595-9
references: 18452693
references: Clin Pharmacol Ther. 2002 Oct;72(4):429-37
references: 12386645
references: Eur J Clin Pharmacol. 2008 Dec;64(12):1163-73
references: 18648788
references: Pharmacotherapy. 2009 Jul;29(7):822-31
references: 19558256
references: Drug Metab Dispos. 2001 May;29(5):656-63
references: 11302931
references: CMAJ. 2009 Mar 31;180(7):713-8
references: 19176635
references: Am J Epidemiol. 2001 Nov 1;154(9):854-64
references: 11682368
references: Eur J Clin Pharmacol. 1998 May;54(3):261-4
references: 9681670
references: Arch Intern Med. 1989 Aug;149(8):1785-9
references: 2788396
references: Int Rev Psychiatry. 2008 Apr;20(2):203-8
references: 18386213
references: Arch Gen Psychiatry. 2009 Aug;66(8):848-56
references: 19652124
references: BMJ. 2005 Apr 23;330(7497):960-2
references: 15845982
references: J Clin Psychopharmacol. 1997 Apr;17(2):102-6
references: 10950472
references: Am J Psychiatry. 2000 Mar;157(3):360-7
references: 10698810
references: J Clin Psychopharmacol. 2005 Dec;25(6):561-4
references: 16282838
references: Am J Psychiatry. 2004 Jul;161(7):1285-9
references: 15229063
references: Pharmacotherapy. 2002 Aug;22(8):1001-6
references: 12173784
references: BMJ. 2010 Feb 08;340:c693
references: 20142325
references: Lancet. 1993 Apr 10;341(8850):967-8
references: 8096308
references: Fundam Clin Pharmacol. 2003 Oct;17(5):517-38
references: 14703714
references: Circulation. 1995 Feb 15;91(4):999-1005
references: 7531624
references: J Clin Psychopharmacol. 2007 Feb;27(1):28-34
references: 17224709